1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
DongKook Pharmaceutical Co., Ltd.

DongKook Pharmaceutical Co., Ltd.

KKRX:086450
24,450.00
KRW
+550.00
(+2.30%)
1,830.17EPS
14.17P/E
1.06TMarket Cap
Nov 13Next Earn
DongKook Pharmaceutical Co., Ltd.
KRX:086450
(Korea Stock Exchange)

Recent

price

24,450.00

P/E

ratio

14.17

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
3,203.57
3,634.39
4,087.2
4,804.86
5,124.82
5,914.02
7,046.9
8,071.51
9,119.34
2,194.2
12,726.66
13,525.52
15,047.7
16,486.99
18,334.41
20,876.53
21,318.4
Revenue per Share
391.6
458.26
505.8
378
478.4
624
925.2
901
1,068.2
256.2
1,273
1,146
1,203
1,064
1,382
1,487
1,664.91
Basic EPS, GAAP
32.3
131.14
190.45
343.18
207.36
399.24
677.89
381.58
-969.62
201.54
403.21
-154.05
-234.73
55.1
1,022.37
512.72
603.38
Free Cash Flow per Basic Share
60.29
76
76.01
75.61
56.4
60.02
60
79.99
103.99
21.16
162.87
183.23
183.07
181.58
187.67
208.2
- -
Dividend per Share
2,640.49
2,970.24
3,348.92
3,644.29
4,009.97
4,542.09
5,399.87
6,005.66
7,113.75
8,248.08
9,351.51
10,334.43
11,410.55
12,381.26
13,716.51
14,713.6
15,057.91
Book Value per Share
2,543.52
2,891.1
3,259.25
3,518.21
3,895.71
4,422.63
5,279.66
5,907.23
7,014.57
8,151.52
9,185.42
10,177.07
11,163.17
12,013.61
12,749.92
13,777.71
14,115.9
Tangible Book Value per Share
44
44
44
44
44
44
44
44
44
220
44
44
44
44
44
44
45
Basic Weighted Avg Shares
141,509
160,341
180,296
213,086
226,014
259,930
309,690
354,768
400,807
482,280
559,103
594,193
661,647
730,994
812,166
926,884
954,164
Sales/Revenue/Turnover
15.94
16.53
15.01
11.51
11.75
12.93
15.15
14.11
13.75
14.25
15.18
10.64
11.18
9.15
9.9
10.42
10.33
Operating Margin (%)
4,219
4,773
5,410
5,190
4,360
5,656
5,752
7,348
9,095
13,616
15,112
17,358
19,187
21,098
28,462
31,712
32,578
Depreciation Expense
17,298
20,217
22,312
16,764
21,098
27,426
40,660
39,602
46,949
56,312
55,925
50,345
52,896
47,175
61,219
66,020
74,518
Net Income, GAAP
26.31
23.99
23.57
35.29
26.1
26
24.83
22.58
21.67
21.92
27.68
24.14
20.22
19.67
26.44
20.15
17.77
Effective Tax Rate (%)
12.22
12.61
12.38
7.87
9.33
10.55
13.13
11.16
11.71
11.68
10
8.47
7.99
6.45
7.54
7.12
7.81
Profit Margin (%)
78,727
86,150
99,755
108,892
120,391
136,345
161,106
191,005
208,061
229,011
233,868
177,625
186,782
188,044
237,315
297,982
293,580
Working Capital
500
- -
- -
700
1,603
1,485
482
360
40,120
43,199
52,115
13,687
27,449
20,219
28,627
20,854
21,517
LT Debt
116,492
131,040
147,747
162,239
176,565
200,615
238,337
279,495
331,612
385,420
435,806
481,645
531,064
576,174
678,976
763,739
780,603
Total Equity
14.22
14.77
14.24
9.9
11.04
12.37
15.06
14.09
12.46
12.55
12.58
8.69
9.87
8.48
8.26
9.46
9.8
Return on Invested Capital (%)
15.44
15.82
15.63
10.67
12.24
14.19
17.99
14.45
13.25
12.99
11.64
9.22
9.26
8.03
8.98
7.47
8.26
Return on Capital (%)
16
16.34
16.01
10.83
12.48
14.59
18.61
15.8
16.29
16.68
14.46
11.64
11.07
9.02
10.67
10.42
11.56
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
53,288
55,385
46,462
LT Borrowings
15,786
15,687
15,588
LT Finance Leases
4,023
5,167
5,929
Preferred Equity and Hybrid Capital
173
- -
- -
Shares Outstanding
44
45
45
Market Capitalization
838,122
773,649
1,064,613

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
548,347
565,396
571,725
Cash, Cash Equivalents & STI
115,891
127,102
118,361
Accounts Receivable, Net
214,409
222,159
231,149
Inventories
178,076
175,249
183,336
Total Current Liabilities
263,080
267,414
278,145
Payables & Accruals
- -
- -
- -
ST Debt
53,288
55,385
46,462
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.36%
11.92%
12.48%
Free Cash Flow
90.28%
298.95%
-49.74%
Net Income, GAAP
10.53%
4.38%
7.84%
Sales/Revenue/Turnover
13.63%
10.67%
14.12%
Total Cash Common Dividend
- -
- -
11.19%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
196,821
203,538
200,879
210,929
812,166
2025
223,736
233,461
226,809
242,878
926,884
2026
251,016
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
445
307
436
196.28
1,382
2025
372
355.9
449.45
306.23
1,487
2026
553.06
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
187.67
2025
- -
- -
- -
- -
208.2
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
DongKook Pharmaceutical Co., Ltd. (086450.KQ) manufactures and distributes pharmaceutical products, focusing on active pharmaceutical ingredients (APIs), finished dosage formulations, and healthcare solutions. The company produces a range of generic drugs and APIs including antibiotics such as cefazolin and cefuroxime, anti-inflammatories like ibuprofen and naproxen, and cardiovascular medications including atorvastatin and rosuvastatin; it also offers over-the-counter products, veterinary pharmaceuticals, and contract manufacturing services for third-party clients. Operations span South Korea as its primary market, with exports to Asia, Europe, and North America. Founded in 1975 and headquartered in Iksan, South Jeolla Province, South Korea, the company serves hospitals, pharmacies, and international distributors in the generic pharmaceuticals segment. In recent developments, DongKook Pharmaceutical expanded its production capacity through a new API facility in 2024 and formed a strategic partnership with a leading Indian biotech firm for biosimilar development in oncology treatments.